The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.View on euronews ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in ...

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

A new film from Eli Lilly sounds like a recruitment ad, but it doubles as a brand manifesto to showcase the pharmaceutical ...

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...

The boss of the drugs giant Novo Nordisk has been sacked after falling behind in the global race to develop weight-loss medication.

Jorgensen became CEO in January 2017 and the company’s market capitalization has more than tripled during his tenure. Novo was first to market with Wegovy and its sister drug Ozempic for diabetes, but ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is ...

The Danish company said Jorgensen is leaving by mutual agreement with the board, though he’ll continue as chief 'for a period ...